KYAT1 and pancreatic neoplasm: This metabolic adaptability of tumors explains the current outcomes of single‐targeted GLS1 inhibition in pancreatic cancer and justifies the need for a more strategic approach, specifically by the combination of GLS1 and GTK inhibition, aiming at both main and adaptive metabolic networks.